Gene · 1285
Papers2,040
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,040
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic significance and multivariate modeling of COL4A family genes and HMGA2 in glioma. | Front Pharmacol | 2025 | 40351420 | PubTator, text mining | PubMed |
| [New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report]. | G Ital Nefrol | 2025 | 40332975 | PubTator, text mining | PubMed |
| Mechanism of etoposide resistance in small cell lung cancer and the potential therapeutic options. | Med Oncol | 2025 | 40257680 | PubTator, text mining | PubMed |
| Phenotype-genotype correlations in patients with Alport syndrome from the Polish population. | J Nephrol | 2025 | 40237890 | PubTator, text mining | PubMed |
| Whole exome sequencing shows novel COL4A3 and COL4A4 variants as causes of Alport syndrome in Rio Grande do Norte, Brazil. | BMC Genomics | 2025 | 40169949 | PubTator, text mining | PubMed |
| Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel. | Urolithiasis | 2025 | 40126616 | PubTator, text mining | PubMed |
| Crosslinking stabilization strategy: A novel approach to cartilage-like repair of annulus fibrosus (AF) defects. | Mater Today Bio | 2025 | 40124345 | PubTator, text mining | PubMed |
| Pathogenic variants in the Alport genes are prevalent in the Singapore multiethnic population with highest frequency in the Chinese. | Sci Rep | 2025 | 40044766 | PubTator, text mining | PubMed |
| Molecular Review of Suspected Alport Syndrome Patients-A Single-Centre Experience. | Genes (Basel) | 2025 | 40004525 | PubTator, text mining | PubMed |
| COL4A5 Intronic Variants at Third to Fifth Nucleotides Cause Alport Syndrome. | Kidney Int Rep | 2025 | 39990911 | PubTator, text mining | PubMed |
| Renal Phenotype Variations among Families with Autosomal Alport Syndrome: Potential Role of Modifier Genes. | Kidney360 | 2025 | 39951344 | PubTator, text mining | PubMed |
| Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review. | Mol Genet Genomic Med | 2025 | 39924725 | PubTator, text mining | PubMed |
| A Novel Loss-of-Function Variant in COL4A3 in a Consanguineous Moroccan Family Displaying the Alport Syndrome with Variable Clinical Expression. | Mol Syndromol | 2025 | 39911173 | PubTator, text mining | PubMed |
| A 15-year experience highlighting the spectrum of Alport kidney disease in the pediatric population and novel genetic variants in COL4A3-5. | Pediatr Nephrol | 2025 | 39907758 | PubTator, text mining | PubMed |
| The landscape of immunogenic cell death-related genes predicts the overall survival and immune infiltration status of non-small-cell lung carcinoma. | Heliyon | 2025 | 39834423 | PubTator, text mining | PubMed |
| Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndrome. | Nephrol Dial Transplant | 2025 | 39810285 | PubTator, text mining | PubMed |
| Challenging the narrative of Alport syndrome spectrum: no link with cystic phenotype. | Nephrol Dial Transplant | 2025 | 39694697 | PubTator, text mining | PubMed |
| Synergistic toxicity of compound heterozygous mutations in the COL4A3 gene causes end-stage renal disease in A large family of Alport syndrome. | Gene | 2025 | 39615805 | PubTator, text mining | PubMed |
| Correction: Slowly progressive autosomal dominant Alport Syndrome due to COL4A3 splicing variant. | Eur J Hum Genet | 2025 | 39587357 | PubTator, text mining | PubMed |
| Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin. | Nephrol Dial Transplant | 2025 | 39562282 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1285/papers?page=7